 |
| |
|
Early pregnancy losses including incomplete abortion and miscarriage occur in 15-20% of all pregnancies and are most commonly treated surgically with dilatation and curettage, or manual or electric vacuum aspiration. While these techniques are safe and effective when performed by a trained professional, both women and providers can benefit from an inexpensive, less invasive alternative such as misoprostol. Medical management of incomplete abortion and miscarriage with misoprostol has been used successfully for some time and in a variety of settings without clear guidelines as to the appropriate, dose, route, timing and precautions.
In June 2004, RHTP and Gynuity Health Projects convened a group of experts with epidemiological, clinical and programmatic expertise in use of misoprostol for the treatment of incomplete abortion and miscarriage to develop consensus guidelines for this indication.
Download:
|
|
|
| |
|
|
Consensus Guidelines: Misoprostol for Abortion Induction in Pregnancies Up to 9 Weeks LMP
|
|
Gynuity Health Projects
Gynuity Health Projects is a research and technical assistance organization dedicated to the idea that all people should have access to the fruits of medical science and technology development.
|
Misoprostol: An Emerging Technology for Women's Health [PDF, 565KB]
The report highlights the potential of misoprostol to improve women’s health. The meeting summarized in this report was organized because a large body of scientific work supporting the use of misoprostol for induced abortion, uterine evacuation after pregnancy failure, cervical priming, labor induction, and management of the third stage of labor, had not been synthesized in an accessible way.
|
|
|
|
|
